AstraZeneca Pharma India receives CDSCO nod for expanded use of Imfinzi in bladder cancer Ruchika Sharma14 July 2025 5:43 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate...
AstraZeneca Imfinzi approved in EU for muscle-invasive bladder cancer Ruchika Sharma6 July 2025 11:00 AM ISTCambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult patients...
AstraZeneca Pharma India gets CDSCO nod for expanded use of Imfinzi in Endometrial Cancer Ruchika Sharma2 July 2025 12:01 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation...
AstraZeneca Imfinzi recommended for approval in EU for adults with muscle-invasive bladder cancer Ruchika Sharma29 May 2025 2:15 PM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the...
CDSCO panel Approves Astrazeneca Pharma India's Protocol Amendment proposal to study Durvalumab-Tremelimumab Dr. Divya Colin17 May 2025 6:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved Astrazeneca Pharma...
AstraZeneca Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer Ruchika Sharma4 April 2025 3:30 PM ISTCambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union...
AstraZeneca gets USFDA approval for perioperative Imfinzi for bladder cancer Ruchika Sharma1 April 2025 2:15 PM ISTImfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.
AstraZeneca Imfinzi approved in EU for limited stage small cell lung cancer Ruchika Sharma17 March 2025 10:30 AM ISTThe safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.
AstraZeneca Imfinzi based perioperative regimen recommended for approval in EU for resectable non-small cell lung cancer Ruchika Sharma4 March 2025 10:15 AM ISTAstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for...
CDSCO nod to AstraZeneca Pharma India to import, sell lung cancer treatment medicine Ruchika Sharma3 March 2025 4:26 PM ISTAstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control Organisation, Directorate...
AstraZeneca Imfinzi granted priority review by USFDA for muscle-invasive bladder cancer Ruchika Sharma7 Dec 2024 12:30 PM ISTCambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review...
AstraZeneca Imfinzi gets USFDA nod for limited-stage small cell lung cancer Ruchika Sharma6 Dec 2024 11:00 AM ISTAstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer...
